The incidence and relative risk of stroke in patients with schizophrenia: A five-year follow-up study

Schizophrenia Research

Volumn 138, Issue 1, 2012, Pages 41-47

  Tsai, Kuan Yi ^a   Lee, Ching Chih ^b,c,d   Chou, Yu Mei ^e   Su, Chao Yueh ^f   Chou, Frank Huang Chih ^a,g  

^a KAI SUAN PSYCHIATRIC HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

^e KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f I SHOU UNIVERSITY   (Taiwan)

^g MEIHO UNIVERSITY   (Taiwan)

Author keywords

National health insurance research database (NHIRD); Schizophrenia; Stroke incidence

Indexed keywords

ADULT; ARTICLE; CAUSE OF DEATH; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; STROKE; SURVIVAL RATE; TAIWAN;

ADULT; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; SCHIZOPHRENIA; STROKE;

EID: 84862831071     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.02.013     Document Type: Article

References (61)

1. Bar K.J., Letzsch A., Jochum T., Wagner G., Greiner W., Sauer H. Loss of efferent vagal activity in acute schizophrenia. J. Psychiatr. Res. 2005, 39(5):519-527.
2. Bih S.H., Chien I.C., Chou Y.J., Lin C.H., Lee C.H., Chou P. The treated prevalence and incidence of bipolar disorder among national health insurance enrollees in Taiwan, 1996-2003. Soc. Psychiatry Psychiatr. Epidemiol. 2008, 43(11):860-865.
3. Bureau of National Health Insurance Website http://www.nhi.gov.tw/information/bulletin_file/421_0890036465-19.doc.
4. Burke T.A., Venketasubramanian R.N. The epidemiology of stroke in the East Asian region: a literature-based review. Int. J. Stroke 2006, 1(4):208-215.
5. Cadilhac D.A., Dewey H.M., Vos T., Carter R., Thrift A.G. The health loss from ischemic stroke and intracerebral hemorrhage: evidence from the North East Melbourne Stroke Incidence Study (NEMESIS). Health Qual. Life Outcomes 2010, 8:49.
6. Capasso R.M., Lineberry T.W., Bostwick J.M., Decker P.A., St S.J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr. Res. 2008, 98(1-3):287-294.
7. Chang J.S., Yoo C.S., Yi S.H., et al. Changes in heart rate dynamics of patients with schizophrenia treated with risperidone. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(6):924-929.
8. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987, 40:373-383.
9. Chen C.Y., Liu C.Y., Su W.C., Huang S.L., Lin K.M. Factors associated with the diagnosis of neurodevelopmental disorders: a population-based longitudinal study. Pediatrics 2007, 119(2):e435-e443.
10. Chen Y.H., Lin H.C., Lin H.C. Poor clinical outcomes among pneumonia patients with schizophrenia. Schizophr. Bull. 2010, 37(5):1088-1094.
11. Chiang T.L. Taiwan's 1995 health care reform. Health Policy 1997, 39(3):225-239.
12. Chien I.C., Chou Y.J., Lin C.H., Bih S.H. Prevalence and incidence of schizophrenia among national health insurance enrollees in Taiwan, 1996-2001. Psychiatry Clin. Neurosci. 2004, 58:611-618.
13. Chou F.H., Tsai K.Y., Su C.Y., Lee C.C. The incidence and relative risk factors of developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophr. Res. 2011, 129(2-3):97-103.
14. Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 2004, 37(1):1-11.
15. Curkendall S.M., Mo J., Glasser D.B., Rose S.M., Jones J.K. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J. Clin. Psychiatry 2004, 65(5):715-720.
16. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 1992, 45(6):613-619.
17. Druss B.G. Improving medical care for persons with serious mental illness: challenges and solutions. J. Clin. Psychiat. 2007, 68(Suppl. 4):40-44.
18. Druss B.G., Rosenheck R.A. Mental disorders and access to medical care in the United States. Am. J. Psychiatry 1998, 155(12):1775-1777.
19. Druss B.G., Bradford D.W., Rosenheck R.A., Radford M.J., Krumholz H.M. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 2000, 283(4):506-511.
20. Freedman R. Schizophrenia. N. Engl. J. Med. 2003, 349(18):1738-1749.
21. Henderson D.C. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?. CNS Drugs 2002, 16(2):77-89.
22. Hennekens C.H., Hennekens A.R., Hollar D., Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 2005, 150(6):1115-1121.
23. Hogan A.M., Winter D.C. Does practice make perfect?. Ann. Surg. Oncol. 2008, 15(5):1267-1270.
24. Homel P., Casey D., Allison D.B. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr. Res. 2002, 55(3):277-284.
25. Kang J.H., Xirasagar S., Lin H.C. Lower mortality among stroke patients with schizophrenia: a nationwide population-based study. Psychosom. Med. 2011, 73(1):106-111.
26. Kapral M.K., Fang J., Hill M.D., et al. Sex differences in stroke care and outcomes: results from the Registry of the Canadian Stroke Network. Stroke 2005, 36(4):809-814.
27. Kisely S., Campbell L.A., Wang Y. Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare. Br. J. Psychiatry 2009, 195(6):545-550.
28. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr. Scand. 2007, 116(5):317-333.
29. Leys D., Deplanque D., Mounier-Vehier C., kowiak-Cordoliani M.A., Lucas C., Bordet R. Stroke prevention: management of modifiable vascular risk factors. J. Neurol. 2002, 249(5):507-517.
30. Liao D.L., Yang J.Y., Lee S.M., Chen H., Tsai S.J. Smoking in chronic schizophrenic inpatients in Taiwan. Neuropsychobiology 2002, 45(4):172-175.
31. Liao C.H., Chang C.S., Wei W.C., et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr. Res. 2011, 126(1-3):110-116.
32. Lin H.C., Lin Y.J., Liu T.C., Chen C.S., Chiu W.T. Urbanization and stroke prevalence in Taiwan: analysis of a nationwide survey. J. Urban Health 2007, 84(4):604-614.
33. Lin H.C., Hsiao F.H., Pfeiffer S., Hwang Y.T., Lee H.C. An increased risk of stroke among young schizophrenia patients. Schizophr. Res. 2008, 101(1-3):234-241.
34. McCreadie R.G. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br. J. Psychiatry 2003, 183:534-539.
35. McFadden E., Luben R., Wareham N., Bingham S., Khaw K.T. Social class, risk factors, and stroke incidence in men and women: a prospective study in the European prospective investigation into cancer in Norfolk cohort. Stroke 2009, 40(4):1070-1077.
36. Melkersson K., Dahl M.L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004, 64(7):701-723.
37. Meyer J.M., Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004, 70(1):1-17.
38. Meyer J., Koro C.E., L'Italien G.J. The metabolic syndrome and schizophrenia: a review. Int. Rev. Psychiatry 2005, 17(3):173-180.
39. Nasrallah H.A., Newcomer J.W. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J. Clin. Psychopharmacol. 2004, 24(5 Suppl 1):S7-S14.
40. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
41. Newcomer J.W., Haupt D.W., Fucetola R., et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 2002, 59(4):337-345.
42. Newman S.C., Bland R.C. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can. J. Psychiatry 1991, 36(4):239-245.
43. NHI. NHI profile (updated 7 july 2008). http://www.nhi.gov.tw/english/webdata.asp?menu=11&menu_id=290&webdata_id=1884.
44. Oud M.J., Meyboom-de J.B. Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam. Pract. 2009, 10:32.
45. Peng S.Y., Chuang Y.C., Kang T.W., et al. Random forest can predict 30-day mortality of spontaneous intracerebral hemorrhage with remarkable discrimination. Eur. J. Neurol. 2010, 17:945-950.
46. Penn D.L., Martin J. The stigma of severe mental illness: some potential solutions for a recalcitrant problem. Psychiatr. Q. 1998, 69(3):235-247.
47. Reeves M.J., Bushnell C.D., Howard G., et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008, 7(10):915-926.
48. Ruetsch O., Viala A., Bardou H., Martin P., Vacheron M.N. Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management. Encephale 2005, 31(4 Pt 1):507-516.
49. Sacchetti E., Turrina C., Valsecchi P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf. 2010, 33(4):273-288.
50. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry 2007, 64(10):1123-1131.
51. Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical anti-psychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005, 294(15):1934-1943.
52. Schulman K.A., Berlin J.A., Harless W., et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N. Engl. J. Med. 1999, 340(8):618-626.
53. Shirzadi A.A., Ghaemi S.N. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv. Rev. Psychiatry 2006, 14(3):152-164.
54. Tandon R., Halbreich U. The second-generation 'atypical' antipsychotics: similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology 2003, (Suppl 1):1-7.
55. Thrift A.G., Dewey H.M., Macdonell R.A., McNeil J.J., Donnan G.A. Incidence of the major stroke subtypes: initial findings from the North East Melbourne stroke incidence study (NEMESIS). Stroke 2001, 32(8):1732-1738.
56. Tsay J.H., Lee C.H., Hsu Y.J., et al. Disparities in appendicitis rupture rate among mentally ill patients. BMC Publ. Health 2007, 7:331.
57. Tseng C.H. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care 2004, 27(7):1605-1609.
58. Villareal R.P., Liu B.C., Massumi A. Heart rate variability and cardiovascular mortality. Curr. Atheroscler. Rep. 2002, 4(2):120-127.
59. Wood J.B., Evenson R.C., Cho D.W., Hagan B.J. Mortality variations among public mental health patients. Acta Psychiatr. Scand. 1985, 72(3):218-229.
60. Wu R.R., Zhao J.P., Liu Z.N., Zhai J.G., Guo X.F., Guo W.B., Tang J.S. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl). 2006, 186(4):572-578.
61. Wyller T.B. Stroke and gender. J. Gend. Specif. Med. 1999, 2(3):41-45.